Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Want to cut your energy bills? Here’s how five experts are doing it 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Heidelberg, Germany, May 30, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at the Jefferies 2017 Global Healthcare Conference on Tuesday, June 6, 2017 at 2:00 p.m. (ET) in New York.
A live webcast of the conference presentation can be accessed through the "Events" section on the "Investors & Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the presentation will be available from Affimed's website for 30 days following the conference.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
IR Contact:
Caroline Stewart, Head IR
Phone: +1 347394 6793
E-Mail: [email protected] or [email protected]
Media Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected]
